In this context, Bay 11–7082 with its NFκB inhibitory potential29 and its ability to deplete GSH at pharmacologically relevant concentrations (Fig. 3a) might also be taken into account for the treatment of patients with hematologic malignancies and inflammatory diseases. This evidence concerns the gene NFKB1 and hematologic disorder.